Traditional prostate cancer features fail to predict hormone therapy benefit

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer -such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles- after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who will benefit more from adding hormone therapy to postoperative radiation.